William D. Waddill
Director at Arrowhead Pharmaceuticals, Inc. (ARWR); Director at Protagonist Therapeutics, Inc (PTGX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jun 25SEC | PTGXProtagonist Therapeutics, Inc | Sell Plan | 9,0007,825 held (−53%) | $117.94 | $1.1M | +21.9% |
| Jun 11SEC | PTGXProtagonist Therapeutics, Inc | Sell Plan | 9,0007,825 held (−53%) | $107.68 | $969K | +33.5% |
| Jun 1SEC | PTGXProtagonist Therapeutics, Inc | Sell Plan | 9,0007,825 held (−53%) | $99.64 | $897K | +44.2% |
| Feb 6SEC | PTGXProtagonist Therapeutics, Inc | Sell | 20,0007,825 held (−72%) | $83.68 | $1.7M | +71.8% |
| Dec 23SEC | ARWRArrowhead Pharmaceuticals, Inc. | Sell Plan | 2,41662,514 held (−4%) | $66.66 | $161K | -5.9% |
| Dec 23SEC | ARWRArrowhead Pharmaceuticals, Inc. | Sell Plan | 5,45157,063 held (−9%) | $68.01 | $371K | -7.7% |
| Dec 23SEC | ARWRArrowhead Pharmaceuticals, Inc. | Sell Plan | 50056,563 held (−1%) | $68.53 | $34K | -8.4% |
| Oct 14SEC | PTGXProtagonist Therapeutics, Inc | Sell Plan | 4,00013,130 held (−23%) | $69.25 | $277K | +107.6% |
| Oct 14SEC | PTGXProtagonist Therapeutics, Inc | Sell Plan | 8,0005,130 held (−61%) | $87.81 | $702K | +63.7% |
- Sell
Director William D. Waddill sold $1.1M of PTGX at $117.94 — cuts the stake by 53%; pre-scheduled 10b5-1 plan sale.
- Sell
Director William D. Waddill sold $969K of PTGX at $107.68 — cuts the stake by 53%; pre-scheduled 10b5-1 plan sale.
- Sell
Director William D. Waddill sold $897K of PTGX at $99.64 — cuts the stake by 53%; pre-scheduled 10b5-1 plan sale.
- Sell
Director William D. Waddill sold $1.7M of PTGX at $83.68 — cuts the stake by 72%.
- Sell
Director William D. Waddill sold $161K of ARWR at $66.66 — pre-scheduled 10b5-1 plan sale.
- Sell
Director William D. Waddill sold $371K of ARWR at $68.01 — pre-scheduled 10b5-1 plan sale.